Novel Designs and End Points for Phase II Clinical Trials

Alex Adjei, Michaele Christian, Percy Ivy

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The large number of negative phase III trials in oncology over the last several years has renewed interest in refining phase II oncology clinical trials to maximize the chances of success in phase III testing. More efficient phase II study designs will improve our ability to identify promising agents for testing while accurately identifying nonefficacious agents. Recognizing that new paradigms of phase II trial designs need to be developed, the Clinical Trial Design Task Force of the National Cancer Institute (NCI) Investigational Drug Steering Committee has tackled the question of improving efficiency of phase II clinical trials. In this issue of CCR Focus, four of the major topics discussed are presented. First, the task force recommended that alternate phase II end points should be studied. Second, depending on the characteristics of the specific trial and study population, historical controls or a randomized design may be more appropriate. Third, rational incorporation of biomarkers into phase II trials should be encouraged. Last, novel imaging modalities will be critical in evaluating the clinical benefit of new cytostatic agents.

Original languageEnglish (US)
Pages (from-to)1866-1872
Number of pages7
JournalClinical Cancer Research
Volume15
Issue number6
DOIs
StatePublished - Mar 15 2009
Externally publishedYes

Fingerprint

Phase II Clinical Trials
Advisory Committees
Pharmacy and Therapeutics Committee
Investigational Drugs
Population Control
National Cancer Institute (U.S.)
Cytostatic Agents
Biomarkers
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel Designs and End Points for Phase II Clinical Trials. / Adjei, Alex; Christian, Michaele; Ivy, Percy.

In: Clinical Cancer Research, Vol. 15, No. 6, 15.03.2009, p. 1866-1872.

Research output: Contribution to journalArticle

Adjei, Alex ; Christian, Michaele ; Ivy, Percy. / Novel Designs and End Points for Phase II Clinical Trials. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 6. pp. 1866-1872.
@article{ea86e52750fd4133a5c9668c968be945,
title = "Novel Designs and End Points for Phase II Clinical Trials",
abstract = "The large number of negative phase III trials in oncology over the last several years has renewed interest in refining phase II oncology clinical trials to maximize the chances of success in phase III testing. More efficient phase II study designs will improve our ability to identify promising agents for testing while accurately identifying nonefficacious agents. Recognizing that new paradigms of phase II trial designs need to be developed, the Clinical Trial Design Task Force of the National Cancer Institute (NCI) Investigational Drug Steering Committee has tackled the question of improving efficiency of phase II clinical trials. In this issue of CCR Focus, four of the major topics discussed are presented. First, the task force recommended that alternate phase II end points should be studied. Second, depending on the characteristics of the specific trial and study population, historical controls or a randomized design may be more appropriate. Third, rational incorporation of biomarkers into phase II trials should be encouraged. Last, novel imaging modalities will be critical in evaluating the clinical benefit of new cytostatic agents.",
author = "Alex Adjei and Michaele Christian and Percy Ivy",
year = "2009",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-08-2035",
language = "English (US)",
volume = "15",
pages = "1866--1872",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Novel Designs and End Points for Phase II Clinical Trials

AU - Adjei, Alex

AU - Christian, Michaele

AU - Ivy, Percy

PY - 2009/3/15

Y1 - 2009/3/15

N2 - The large number of negative phase III trials in oncology over the last several years has renewed interest in refining phase II oncology clinical trials to maximize the chances of success in phase III testing. More efficient phase II study designs will improve our ability to identify promising agents for testing while accurately identifying nonefficacious agents. Recognizing that new paradigms of phase II trial designs need to be developed, the Clinical Trial Design Task Force of the National Cancer Institute (NCI) Investigational Drug Steering Committee has tackled the question of improving efficiency of phase II clinical trials. In this issue of CCR Focus, four of the major topics discussed are presented. First, the task force recommended that alternate phase II end points should be studied. Second, depending on the characteristics of the specific trial and study population, historical controls or a randomized design may be more appropriate. Third, rational incorporation of biomarkers into phase II trials should be encouraged. Last, novel imaging modalities will be critical in evaluating the clinical benefit of new cytostatic agents.

AB - The large number of negative phase III trials in oncology over the last several years has renewed interest in refining phase II oncology clinical trials to maximize the chances of success in phase III testing. More efficient phase II study designs will improve our ability to identify promising agents for testing while accurately identifying nonefficacious agents. Recognizing that new paradigms of phase II trial designs need to be developed, the Clinical Trial Design Task Force of the National Cancer Institute (NCI) Investigational Drug Steering Committee has tackled the question of improving efficiency of phase II clinical trials. In this issue of CCR Focus, four of the major topics discussed are presented. First, the task force recommended that alternate phase II end points should be studied. Second, depending on the characteristics of the specific trial and study population, historical controls or a randomized design may be more appropriate. Third, rational incorporation of biomarkers into phase II trials should be encouraged. Last, novel imaging modalities will be critical in evaluating the clinical benefit of new cytostatic agents.

UR - http://www.scopus.com/inward/record.url?scp=63449089608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449089608&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2035

DO - 10.1158/1078-0432.CCR-08-2035

M3 - Article

VL - 15

SP - 1866

EP - 1872

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -